Pfizer Dives; Why Lilly's Zepbound Still Looks Like The Weight-Loss Heavyweight

Pfizer Stock Dives On Modest Guidance, Obesity Update; Can It Catch Eli Lilly? | Investor's Business DailyBREAKING: [Stocks Edge Higher As Teradyne, Palantir Surge]---Pfizer (PFE) stock toppled Tuesday after the S&P health giant reaffirmed its modest outlook for 2026 despite easily beating Wall Street's fourth- quarter expectations. The company also provided an update on its obesity treatment, MET-097i, saying patients who tested a weekly dose for 12 weeks followed by monthly doses up to 28 weeks lost, on a ...